Abstract
Background: Polymethyl methacrylate (PMMA) membranes are increasingly recognized for their effectiveness in treating acute kidney injury (AKI) due to their strong adsorption capabilities, particularly for inflammatory mediators like β2-microglobulin and IL-6. These membranes ensure mechanical stability and chemical inertness, minimizing adverse reactions during blood filtration. Summary: In acute conditions such as sepsis and acute respiratory distress syndrome (ARDS), PMMA membranes show promising findings. In sepsis, they may help reduce multiorgan failure by modulating immune responses, although further research is needed to confirm their routine use. For ARDS, PMMA membranes could mitigate “cytokine storms” by adsorbing key cytokines, improving oxygenation and hemodynamic stability, which may reduce ICU stays and reliance on mechanical ventilation. Monitoring biomarkers like IL-6, TNF-α is critical for tracking efficacy and tailoring therapy to individual needs. In chronic conditions, such as hemodialysis for chronic kidney disease, PMMA membranes help lower oxidative stress and β2-microglobulin levels, reducing complications such as amyloidosis. By decreasing oxidative damage, they provide long-term protective benefits for dialysis patients. Key Message: While these advantages are notable, large-scale studies are needed to establish PMMA’s efficacy, refine treatment protocols, and confirm its broader role in acute and chronic disease management. The potential of PMMA membranes highlights their value, but standardized clinical evidence is necessary for widespread adoption.
Journal Section:
Hemodialysis
References
1.
Redtenbacher
J
. Ueber die Zerlegungsprodukte des Glyceryloxydes durch trockene Destillation
. Justus Liebigs Ann Chem
. 1843
;47
(2
):113
–48
. 2.
3.
Aoike
I
. Clinical significance of protein adsorbable membranes—long-term clinical effects and analysis using a proteomic technique
. Nephrol Dial Transpl
. 2007
;22
(Suppl 5
):v13
–9
. 4.
Bello
G
, Di Muzio
F
, Maviglia
R
, Antonelli
M
. New membranes for extracorporeal blood purification in septic conditions
. Minerva Anestesiol
. 2012
;78
(11
):1265
–81
.5.
Honore
PM
, Jacobs
R
, Joannes-Boyau
O
, De Regt
J
, De Waele
E
, van Gorp
V
, et al. Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review
. Asaio j
. 2013
;59
(2
):99
–106
. 6.
Ray
P
, Chakraborty
R
, Banik
O
, Banoth
E
, Kumar
P
. Surface engineering of a bioartificial membrane for its application in bioengineering devices
. ACS Omega
. 2023
;8
(4
):3606
–29
. 7.
Ji
H
, Li
Y
, Su
B
, Zhao
W
, Kizhakkedathu
JN
, Zhao
C
. Advances in enhancing hemocompatibility of hemodialysis hollow-fiber membranes
. Adv Fiber Mater
. 2023
;5
(4
):1198
–240
. 8.
Aoike
I
. Long-term clinical experience with PMMA membrane
. In: Ronco
C
, editor. Polymethylmethacrylate: a flexible membrane for a tailored dialysis
. S.Karger AG
; 1999
. Vol. 125
. p. 205
–12
. 9.
Aucella
F
, Vigilante
M
, Gesuete
A
. Review: the effect of polymethylmethacrylate dialysis membranes on uraemic pruritus
. NDT Plus
. 2010
;3
(Suppl 1
):i8
–11
. 10.
Torii
Y
, Yamada
S
, Yajima
M
, Sugata
T
. Polymethylmethacrylate membrane dialyzer: historic but modern
. Blood Purif
. 2023
;52
(Suppl 1
):8
–14
. 11.
Singer
M
, Deutschman
CS
, Seymour
CW
, Shankar-Hari
M
, Annane
D
, Bauer
M
, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)
. JAMA
. 2016
;315
(8
):801
–10
. 12.
Angus
DC
, van der Poll
T
. van der Poll T: Severe sepsis and septic shock
. N Engl J Med
. 2013
;369
(9
):840
–51
. 13.
Kuwabara
S
, Goggins
E
, Okusa
MD
. The pathophysiology of sepsis-associated AKI
. Clin J Am Soc Nephrol
. 2022
;17
(7
):1050
–69
. 14.
Chousterman
BG
, Swirski
FK
, Weber
GF
. Cytokine storm and sepsis disease pathogenesis
. Semin Immunopathol
. 2017
;39
(5
):517
–28
. 15.
De Rosa
S
, Marengo
M
, Fiorentino
M
, Fanelli
V
, Brienza
N
, Fiaccadori
E
, et al. Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission
. J Nephrol
. 2023
;36
(7
):1731
–42
. 16.
Nalesso
F
, Garzotto
F
, Martello
T
, Contessa
C
, Cattarin
L
, Protti
M
, et al. The patient safety in extracorporeal blood purification treatments of critical patients
. Front Nephrol
. 2022
;2
:871480
. 17.
Kishikawa
T
, Fujieda
H
, Sakaguchi
H
. Comprehensive analysis of cytokine adsorption properties of polymethyl methacrylate (PMMA) membrane material
. J Artif Organs
. 2022
;25
(4
):343
–9
. 18.
Stasi
A
, Franzin
R
, Divella
C
, Sallustio
F
, Curci
C
, Picerno
A
, et al. PMMA-based continuous hemofiltration modulated complement activation and renal dysfunction in LPS-induced acute kidney injury
. Front Immunol
. 2021
;12
:605212
. 19.
Nakada
TA
, Oda
S
, Matsuda
K
, Sadahiro
T
, Nakamura
M
, Abe
R
, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock
. Mol Med
. 2008
;14
(5–6
):257
–63
. 20.
Tanaka
A
, Inaguma
D
, Nakamura
T
, Watanabe
Y
, Ito
E
, Kamegai
N
, et al. Effect of continuous hemodiafiltration using an AN69ST membrane in patients with sepsis
. Ren Replace Ther
. 2017
;3
(1
):12
. 21.
Udy
AA
, Roberts
JA
, Lipman
J
. Clinical implications of antibiotic pharmacokinetic principles in the critically ill
. Intensive Care Med
. 2013
;39
(12
):2070
–82
. 22.
Grotberg
JC
, Reynolds
D
, Kraft
BD
. Management of severe acute respiratory distress syndrome: a primer
. Crit Care
. 2023
;27
(1
):289
. 23.
Grasselli
G
, Calfee
CS
, Camporota
L
, Poole
D
, Amato
MBP
, Antonelli
M
, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies
. Intensive Care Med
. 2023
;49
(7
):727
–59
. 24.
Ronco
C
, Chawla
L
, Husain-Syed
F
, Kellum
JA
. Rationale for sequential extracorporeal therapy (SET) in sepsis
. Crit Care
. 2023
;27
(1
):50
. 25.
Jabaudon
M
, Blondonnet
R
, Ware
LB
. Biomarkers in acute respiratory distress syndrome
. Curr Opin Crit Care
. 2021
;27
(1
):46
–54
. 26.
Ge
R
, Wang
F
, Peng
Z
. Advances in biomarkers for diagnosis and treatment of ARDS
. Diagnostics
. 2023
;13
(21
):3296
. 27.
Swenson
KE
, Swenson
ER
. Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury
. Crit Care Clin
. 2021
;37
(4
):749
–76
. 28.
Park
WY
, Goodman
RB
, Steinberg
KP
, Ruzinski
JT
, Radella
F
2nd, Park
DR
, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome
. Am J Respir Crit Care Med
. 2001
;164
(10 Pt 1
):1896
–903
. 29.
Malard
B
, Lambert
C
, Kellum
JA
. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
. Intensive Care Med Exp
. 2018
;6
(1
):12
. 30.
Donati
G
, Gasperoni
L
, Napoli
M
, Scrivo
A
, Zappulo
F
, Abenavoli
C
, et al. Anti-inflammatory approach in chronic dialysis patients with SARS-CoV-2: ATA or PMMA dialyzers
. Blood Purif
. 2023
;52
(2
):210
–8
. 31.
Matsuda
K
, Moriguchi
T
, Oda
S
, Hirasawa
H
. Efficacy of continuous hemodiafiltration with a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome
. Contrib Nephrol
. 2010
;166
:83
–92
. 32.
Nishida
O
, Nakamura
T
, Kuriyama
N
, Hara
Y
, Yumoto
M
, Shimomura
Y
, et al. Sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) in the treatment of patients with severe sepsis
. Contrib Nephrol
. 2011
;173
:172
–81
. 33.
Kinjoh
K
, Nagamura
R
, Sakuda
Y
, Yamauchi
S
, Takushi
H
, Iraha
T
, et al. Clinical efficacy of blood purification using a polymethylmethacrylate hemofilter for the treatment of severe acute pancreatitis
. Acute Crit Care
. 2022
;37
(3
):398
–406
. 34.
Copaescu
A
, Smibert
O
, Gibson
A
, Phillips
EJ
, Trubiano
JA
. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
. J Allergy Clin Immunol
. 2020
;146
(3
):518
–34.e1
. 35.
Ruiz-Rodríguez
JC
, Plata-Menchaca
EP
, Chiscano-Camón
L
, Ruiz-Sanmartin
A
, Ferrer
R
. Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption
. J Anesth Analg Crit Care
. 2022
;2
(1
):15
. 36.
Meduri
GU
, Headley
S
, Kohler
G
, Stentz
F
, Tolley
E
, Umberger
R
, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time
. Chest
. 1995
;107
(4
):1062
–73
. 37.
Tanaka
T
, Narazaki
M
, Kishimoto
T
. IL-6 in inflammation, immunity, and disease
. Cold Spring Harb Perspect Biol
. 2014
;6
(10
):a016295
. 38.
Qudus
MS
, Tian
M
, Sirajuddin
S
, Liu
S
, Afaq
U
, Wali
M
, et al. The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection
. J Med Virol
. 2023
;95
(4
):e28751
. 39.
Armstrong
L
, Millar
AB
. Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome
. Thorax
. 1997
;52
(5
):442
–6
. 40.
Ciminieri
C
, Woest
ME
, Reynaert
NL
, Heijink
IH
, Wardenaar
R
, Spierings
DCJ
, et al. IL-1β induces a proinflammatory fibroblast microenvironment that impairs lung progenitors' function
. Am J Respir Cel Mol Biol
. 2023
;68
(4
):444
–55
. 41.
Lederer
W
, Stichlberger
M
, Hausdorfer
J
, Fuchs
D
, Mutz
NJ
, Wiedermann
FJ
. Alveolar neopterin, procalcitonin, and IL-6 in relation to serum levels and severity of lung injury in ARDS
. Clin Chem Lab Med
. 2013
;51
(9
):e213
–5
. 42.
Ünüvar
S
, Aslanhan
H
. Clinical significance of increased serum neopterin in chronic kidney failure as a biomarker of cell-mediated immunity
. J Med Biochem
. 2019
;38
:1
–5
. 43.
Cesta
MC
, Zippoli
M
, Marsiglia
C
, Gavioli
EM
, Mantelli
F
, Allegretti
M
, et al. The role of interleukin-8 in lung inflammation and injury: implications for the management of COVID-19 and hyperinflammatory acute respiratory distress syndrome
. Front Pharmacol
. 2021
;12
:808797
. 44.
Liu
KD
, Altmann
C
, Smits
G
, Krawczeski
CD
, Edelstein
CL
, Devarajan
P
, et al. Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study
. Crit Care
. 2009
;13
(4
):R104
. 45.
Ghosh
S
, Khan
NI
, Tsavalas
JG
, Song
E
. Selective detection of lysozyme biomarker utilizing large area chemical vapor deposition-grown graphene-based field-effect transistor
. Front Bioeng Biotechnol
. 2018
;6
:29
. 46.
Yang
G
, Pang
G
, Pang
Z
, Gu
Y
, Mäntysalo
M
, Yang
H
. Non-invasive flexible and stretchable wearable sensors with nano-based enhancement for chronic disease care
. IEEE Rev Biomed Eng
. 2019
;12
:34
–71
. 47.
Fangueiro
JF
, Silva
AM
, Garcia
ML
, Souto
EB
. Current nanotechnology approaches for the treatment and management of diabetic retinopathy
. Eur J Pharm Biopharm
. 2015
;95
(Pt B
):307
–22
. 48.
Wu
T-H
, Tsai
Y-C
, Kuo
F-C
, Lee
MS
, Hu
C-C
, Lee
G-B
. A microfluidic platform for detection and quantification of two biomarkers for rheumatoid arthritis
. Sensor Actuator B Chem
. 2023
;383
:133587
. 49.
García-Faustino
LL
, Morris
SM
, Elston
SJ
, Montelongo
Y
. Detection of biomarkers through functionalized polymers
. Small Methods
. 2024
;8
(1
):2301025
. 50.
Zhou
Y
, Cui
A
, Xiang
D
, Wang
Q
, Huang
J
, Liu
J
, et al. A microfluidic chip with integrated plasma separation for sample-to-answer detection of multiple chronic disease biomarkers in whole blood
. Talanta
. 2024
;280
:126701
. 51.
Guo
Z
, Tian
R
, Xu
W
, Yip
D
, Radyk
M
, Santos
FB
, et al. Highly accurate heart failure classification using carbon nanotube thin film biosensors and machine learning assisted data analysis
. Biosens Bioelectron X
. 2022
;12
:100187
. 52.
Tarng
D-C
, Huang
T-P
, Wei
Y-H
, Liu
T-Y
, Chen
H-W
, Wen Chen
T
, et al. 8-Hydroxy-2′-Deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients
. Am J Kidney Dis
. 2000
;36
:934
–44
.53.
Uji
Y
, Motomiya
Y
, Ando
Y
. A circulating beta 2-microglobulin intermediate in hemodialysis patients
. Nephron Clin Pract
. 2009
;111
(3
):c173
–81
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
